Cargando…
The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth
Little is known about how specific individual viral lineages replicating systemically during acute Human Immunodeficiency Virus or Simian Immunodeficiency Virus (HIV/SIV) infection persist into chronic infection. In this study, we use molecularly barcoded SIV (SIVmac239M) to track distinct viral lin...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639003/ https://www.ncbi.nlm.nih.gov/pubmed/34855793 http://dx.doi.org/10.1371/journal.pone.0260010 |
_version_ | 1784609060489789440 |
---|---|
author | Moriarty, Ryan V. Golfinos, Athena E. Gellerup, Dane D. Schweigert, Hannah Mathiaparanam, Jaffna Balgeman, Alexis J. Weiler, Andrea M. Friedrich, Thomas C. Keele, Brandon F. Davenport, Miles P. Venturi, Vanessa O’Connor, Shelby L. |
author_facet | Moriarty, Ryan V. Golfinos, Athena E. Gellerup, Dane D. Schweigert, Hannah Mathiaparanam, Jaffna Balgeman, Alexis J. Weiler, Andrea M. Friedrich, Thomas C. Keele, Brandon F. Davenport, Miles P. Venturi, Vanessa O’Connor, Shelby L. |
author_sort | Moriarty, Ryan V. |
collection | PubMed |
description | Little is known about how specific individual viral lineages replicating systemically during acute Human Immunodeficiency Virus or Simian Immunodeficiency Virus (HIV/SIV) infection persist into chronic infection. In this study, we use molecularly barcoded SIV (SIVmac239M) to track distinct viral lineages for 12 weeks after intravenous (IV) or intrarectal (IR) challenge in macaques. Two Mafa-A1*063+ cynomolgus macaques (Macaca fascicularis, CM) were challenged IV, and two Mamu-A1*001+ rhesus macaques (Macaca mulatta, RM) were challenged IR with 200,000 Infectious Units (IU) of SIVmac239M. We sequenced the molecular barcode of SIVmac239M from all animals over the 12 weeks of the study to characterize the diversity and persistence of virus lineages. During the first three weeks post-infection, we found ~70–560 times more unique viral lineages circulating in the animals challenged IV compared to those challenged IR, which is consistent with the hypothesis that the challenge route is the primary driver restricting the transmission of individual viral lineages. We also characterized the sequences of T cell epitopes targeted during acute SIV infection, and found that the emergence of escape variants in acutely targeted epitopes can occur on multiple virus templates simultaneously, but that elimination of some of these templates is likely a consequence of additional host factors. These data imply that virus lineages present during acute infection can still be eliminated from the systemic virus population even after initial selection. |
format | Online Article Text |
id | pubmed-8639003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-86390032021-12-03 The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth Moriarty, Ryan V. Golfinos, Athena E. Gellerup, Dane D. Schweigert, Hannah Mathiaparanam, Jaffna Balgeman, Alexis J. Weiler, Andrea M. Friedrich, Thomas C. Keele, Brandon F. Davenport, Miles P. Venturi, Vanessa O’Connor, Shelby L. PLoS One Research Article Little is known about how specific individual viral lineages replicating systemically during acute Human Immunodeficiency Virus or Simian Immunodeficiency Virus (HIV/SIV) infection persist into chronic infection. In this study, we use molecularly barcoded SIV (SIVmac239M) to track distinct viral lineages for 12 weeks after intravenous (IV) or intrarectal (IR) challenge in macaques. Two Mafa-A1*063+ cynomolgus macaques (Macaca fascicularis, CM) were challenged IV, and two Mamu-A1*001+ rhesus macaques (Macaca mulatta, RM) were challenged IR with 200,000 Infectious Units (IU) of SIVmac239M. We sequenced the molecular barcode of SIVmac239M from all animals over the 12 weeks of the study to characterize the diversity and persistence of virus lineages. During the first three weeks post-infection, we found ~70–560 times more unique viral lineages circulating in the animals challenged IV compared to those challenged IR, which is consistent with the hypothesis that the challenge route is the primary driver restricting the transmission of individual viral lineages. We also characterized the sequences of T cell epitopes targeted during acute SIV infection, and found that the emergence of escape variants in acutely targeted epitopes can occur on multiple virus templates simultaneously, but that elimination of some of these templates is likely a consequence of additional host factors. These data imply that virus lineages present during acute infection can still be eliminated from the systemic virus population even after initial selection. Public Library of Science 2021-12-02 /pmc/articles/PMC8639003/ /pubmed/34855793 http://dx.doi.org/10.1371/journal.pone.0260010 Text en © 2021 Moriarty et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Moriarty, Ryan V. Golfinos, Athena E. Gellerup, Dane D. Schweigert, Hannah Mathiaparanam, Jaffna Balgeman, Alexis J. Weiler, Andrea M. Friedrich, Thomas C. Keele, Brandon F. Davenport, Miles P. Venturi, Vanessa O’Connor, Shelby L. The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth |
title | The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth |
title_full | The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth |
title_fullStr | The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth |
title_full_unstemmed | The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth |
title_short | The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth |
title_sort | mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639003/ https://www.ncbi.nlm.nih.gov/pubmed/34855793 http://dx.doi.org/10.1371/journal.pone.0260010 |
work_keys_str_mv | AT moriartyryanv themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT golfinosathenae themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT gellerupdaned themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT schweigerthannah themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT mathiaparanamjaffna themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT balgemanalexisj themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT weilerandream themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT friedrichthomasc themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT keelebrandonf themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT davenportmilesp themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT venturivanessa themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT oconnorshelbyl themucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT moriartyryanv mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT golfinosathenae mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT gellerupdaned mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT schweigerthannah mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT mathiaparanamjaffna mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT balgemanalexisj mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT weilerandream mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT friedrichthomasc mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT keelebrandonf mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT davenportmilesp mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT venturivanessa mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth AT oconnorshelbyl mucosalbarrierandantiviralimmuneresponsescaneliminateportionsoftheviralpopulationduringtransmissionandearlyviralgrowth |